SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on September 26, 2002; DOI 10.1182/blood-2002-06-1822. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-06-1822v1 101/3/1087    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lanham, S. Articles by Packham, G. Search for Related Content PubMed PubMed Citation Articles by Lanham, S. Articles by Packham, G. Related Collections Immunobiology Neoplasia Signal Transduction Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 February 2003, Vol. 101, No. 3, pp. 1087-1093 NEOPLASIA Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia Stuart Lanham, Terry Hamblin, David Oscier, Rachel Ibbotson, Freda Stevenson, and Graham Packham From the Molecular Immunology Group, Tenovus Research Laboratory, Southampton University Hospitals Trust, Southampton, United Kingdom; Cancer Research Oncology Unit, Cancer Sciences Division, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom; and Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom. The mutational status of tumor immunoglobulin VH genes is providing a powerful prognostic marker for chronic lymphocytic leukemia (CLL), with patients having tumors expressing unmutated VH genes being in a less favorable subset. However, the biologic differences correlating with VH gene status that could determine the clinical course of the disease are unknown. Here we show that differing responses to IgM ligation are closely associated with VH gene status. Specifically, 80% of cases with unmutated VH genes showed increased global tyrosine phosphorylation following IgM ligation, whereas only 20% of samples with mutated VH genes responded (P = .0002). There was also an association between response to IgM ligation and expression of CD38 (P = .015). The Syk kinase, critical for transducing B-cell receptor (BCR)- derived signals, was constitutively present in all CLL samples, and there was a perfect association between global phosphorylation and induction of phosphorylation/activation of Syk. Nonresponsiveness to anti-IgM could be circumvented by ligation of IgD (10 of 15 samples tested) or the BCR-associated molecule CD79 (12 of 15 samples tested). These results suggest that multiple mechanisms underlie nonresponsiveness to anti-IgM in CLL and that retained responsiveness to anti-IgM contributes to the poor prognosis associated with the unmutated subset of CLL. The prognostic power of the in vitro response to IgM ligation remains to be determined in a large series, but the simple technology involved may present an alternative or additional test for predicting clinical course. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. M. McElligott, E. N. Maginn, L. M. Greene, S. McGuckin, A. Hayat, P. V. Browne, S. Butini, G. Campiani, M. A. Catherwood, E. Vandenberghe, et al. The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia Cancer Res., November 1, 2009; 69(21): 8366 - 8375. [Abstract] [Full Text] [PDF] A. Vlad, P.-A. Deglesne, R. Letestu, S. Saint-Georges, N. Chevallier, F. Baran-Marszak, N. Varin-Blank, F. Ajchenbaum-Cymbalista, and D. Ledoux Down-regulation of CXCR4 and CD62L in Chronic Lymphocytic Leukemia Cells Is Triggered by B-Cell Receptor Ligation and Associated with Progressive Disease Cancer Res., August 15, 2009; 69(16): 6387 - 6395. [Abstract] [Full Text] [PDF] M. P. Quiroga, K. Balakrishnan, A. V. Kurtova, M. Sivina, M. J. Keating, W. G. Wierda, V. Gandhi, and J. A. Burger B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406 Blood, July 30, 2009; 114(5): 1029 - 1037. [Abstract] [Full Text] [PDF] M. Buchner, S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholome, M. Burger, N. Chevalier, L. Vallat, J. Timmer, J. G. Gribben, et al. Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia Cancer Res., July 1, 2009; 69(13): 5424 - 5432. [Abstract] [Full Text] [PDF] J. A. Burger, M. P. Quiroga, E. Hartmann, A. Burkle, W. G. Wierda, M. J. Keating, and A. Rosenwald High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation Blood, March 26, 2009; 113(13): 3050 - 3058. [Abstract] [Full Text] [PDF] F. Caligaris-Cappio and P. Ghia Novel Insights in Chronic Lymphocytic Leukemia: Are We Getting Closer to Understanding the Pathogenesis of the Disease? J. Clin. Oncol., September 20, 2008; 26(27): 4497 - 4503. [Abstract] [Full Text] [PDF] M. Muzio, B. Apollonio, C. Scielzo, M. Frenquelli, I. Vandoni, V. Boussiotis, F. Caligaris-Cappio, and P. Ghia Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy Blood, July 1, 2008; 112(1): 188 - 195. [Abstract] [Full Text] [PDF] S. Hewamana, S. Alghazal, T. T. Lin, M. Clement, C. Jenkins, M. L. Guzman, C. T. Jordan, S. Neelakantan, P. A. Crooks, A. K. Burnett, et al. The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target Blood, May 1, 2008; 111(9): 4681 - 4689. [Abstract] [Full Text] [PDF] M. Duhamel, I. Arrouss, H. Merle-Beral, and A. Rebollo The Aiolos transcription factor is up-regulated in chronic lymphocytic leukemia Blood, March 15, 2008; 111(6): 3225 - 3228. [Abstract] [Full Text] [PDF] G. Cutrona, M. Colombo, S. Matis, M. Fabbi, M. Spriano, V. Callea, E. Vigna, M. Gentile, S. Zupo, N. Chiorazzi, et al. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells Haematologica, March 1, 2008; 93(3): 413 - 422. [Abstract] [Full Text] [PDF] L. Chen, L. Huynh, J. Apgar, L. Tang, L. Rassenti, A. Weiss, and T. J. Kipps ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia Blood, March 1, 2008; 111(5): 2685 - 2692. [Abstract] [Full Text] [PDF] P. G. Longo, L. Laurenti, S. Gobessi, S. Sica, G. Leone, and D. G. Efremov The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells Blood, January 15, 2008; 111(2): 846 - 855. [Abstract] [Full Text] [PDF] S. Willimott, M. Baou, S. Huf, S. Deaglio, and S. D. Wagner Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4 Haematologica, October 1, 2007; 92(10): 1359 - 1366. [Abstract] [Full Text] [PDF] C. Ian Mockridge, K. N. Potter, I. Wheatley, L. A. Neville, G. Packham, and F. K. Stevenson Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status Blood, May 15, 2007; 109(10): 4424 - 4431. [Abstract] [Full Text] [PDF] L. D. Vallat, Y. Park, C. Li, and J. G. Gribben Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells Blood, May 1, 2007; 109(9): 3989 - 3997. [Abstract] [Full Text] [PDF] S. Gobessi, L. Laurenti, P. G. Longo, S. Sica, G. Leone, and D. G. Efremov ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells Blood, March 1, 2007; 109(5): 2032 - 2039. [Abstract] [Full Text] [PDF] S. T. Abrams, T. Lakum, K. Lin, G. M. Jones, A. T. Treweeke, M. Farahani, M. Hughes, M. Zuzel, and J. R. Slupsky B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase C{beta}II Blood, February 1, 2007; 109(3): 1193 - 1201. [Abstract] [Full Text] [PDF] I. Tinhofer, G. Rubenzer, C. Holler, E. Hofstaetter, M. Stoecher, A. Egle, M. Steurer, and R. Greil Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia Blood, November 1, 2006; 108(9): 2950 - 2956. [Abstract] [Full Text] [PDF] K. Lin, M. A. Glenn, R. J. Harris, A. D. Duckworth, S. Dennett, J. C. Cawley, M. Zuzel, and J. R. Slupsky c-Abl Expression in Chronic Lymphocytic Leukemia Cells: Clinical and Therapeutic Implications. Cancer Res., August 1, 2006; 66(15): 7801 - 7809. [Abstract] [Full Text] [PDF] P.-A. Deglesne, N. Chevallier, R. Letestu, F. Baran-Marszak, T. Beitar, C. Salanoubat, L. Sanhes, J. Nataf, C. Roger, N. Varin-Blank, et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of zap70 expression. Cancer Res., July 15, 2006; 66(14): 7158 - 7166. [Abstract] [Full Text] [PDF] K. N. Potter, C. I. Mockridge, L. Neville, I. Wheatley, M. Schenk, J. Orchard, A. S. Duncombe, G. Packham, and F. K. Stevenson Structural and Functional Features of the B-Cell Receptor in IgG-Positive Chronic Lymphocytic Leukemia. Clin. Cancer Res., March 15, 2006; 12(6): 1672 - 1679. [Abstract] [Full Text] [PDF] N. Chiorazzi and M. Ferrarini Evolving View of the In-Vivo Kinetics of Chronic Lymphocytic Leukemia B Cells Hematology, January 1, 2006; 2006(1): 273 - 278. [Abstract] [Full Text] [PDF] D. J. Allsup, A. S. Kamiguti, K. Lin, P. D. Sherrington, Z. Matrai, J. R. Slupsky, J. C. Cawley, and M. Zuzel B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia Cancer Res., August 15, 2005; 65(16): 7328 - 7337. [Abstract] [Full Text] [PDF] P. Oppezzo, Y. Vasconcelos, C. Settegrana, D. Jeannel, F. Vuillier, M. Legarff-Tavernier, E. Y. Kimura, S. Bechet, G. Dumas, M. Brissard, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia Blood, July 15, 2005; 106(2): 650 - 657. [Abstract] [Full Text] [PDF] A. Petlickovski, L. Laurenti, X. Li, S. Marietti, P. Chiusolo, S. Sica, G. Leone, and D. G. Efremov Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells Blood, June 15, 2005; 105(12): 4820 - 4827. [Abstract] [Full Text] [PDF] S. Nedellec, Y. Renaudineau, A. Bordron, C. Berthou, N. Porakishvili, P. M. Lydyard, J.-O. Pers, and P. Youinou B Cell Response to Surface IgM Cross-Linking Identifies Different Prognostic Groups of B-Chronic Lymphocytic Leukemia Patients J. Immunol., March 15, 2005; 174(6): 3749 - 3756. [Abstract] [Full Text] [PDF] L. Chen, J. Apgar, L. Huynh, F. Dicker, T. Giago-McGahan, L. Rassenti, A. Weiss, and T. J. Kipps ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia Blood, March 1, 2005; 105(5): 2036 - 2041. [Abstract] [Full Text] [PDF] N. Chiorazzi, K. R. Rai, and M. Ferrarini Chronic Lymphocytic Leukemia N. Engl. J. Med., February 24, 2005; 352(8): 804 - 815. [Full Text] [PDF] G. Dighiero CLL Biology and Prognosis Hematology, January 1, 2005; 2005(1): 278 - 284. [Abstract] [Full Text] [PDF] G. Tobin, U. Thunberg, K. Karlsson, F. Murray, A. Laurell, K. Willander, G. Enblad, M. Merup, J. Vilpo, G. Juliusson, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia Blood, November 1, 2004; 104(9): 2879 - 2885. [Abstract] [Full Text] [PDF] A. Rodriguez, N. Martinez, F. I. Camacho, E. Ruiz-Ballesteros, P. Algara, J.-F. Garcia, J. Menarguez, T. Alvaro, M. F. Fresno, F. Solano, et al. Variability in the Degree of Expression of Phosphorylated I{kappa}B{alpha} in Chronic Lymphocytic Leukemia Cases With Nodal Involvement Clin. Cancer Res., October 15, 2004; 10(20): 6796 - 6806. [Abstract] [Full Text] [PDF] F. K. Stevenson and F. Caligaris-Cappio Chronic lymphocytic leukemia: revelations from the B-cell receptor Blood, June 15, 2004; 103(12): 4389 - 4395. [Abstract] [Full Text] [PDF] T. D. Shanafelt, S. M. Geyer, and N. E. Kay Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL Blood, February 15, 2004; 103(4): 1202 - 1210. [Abstract] [Full Text] [PDF] T. J. Hamblin CD38: what is it there for? Blood, September 15, 2003; 102(6): 1939 - 1940. [Full Text] [PDF] K. N. Potter, J. Orchard, E. Critchley, C. I. Mockridge, A. Jose, and F. K. Stevenson Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire Blood, April 15, 2003; 101(8): 3082 - 3084. [Abstract] [Full Text] [PDF] D. F. Jelinek, R. C. Tschumper, G. A. Stolovitzky, S. J. Iturria, Y. Tu, J. Lepre, N. Shah, and N. E. Kay Identification of a Global Gene Expression Signature of B-Chronic Lymphocytic Leukemia Mol. Cancer Res., March 1, 2003; 1(5): 346 - 361. [Abstract] [Full Text] [PDF] M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps Biology and Treatment of Chronic Lymphocytic Leukemia Hematology, January 1, 2003; 2003(1): 153 - 175. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020